The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Characterization of Notch1 Antibodies That Inhibit Signaling of Both Normal and Mutated Notch1 Receptors
Open accessAbstract
BACKGROUND: Notch receptors normally play a key role in guiding a variety of cell fate decisions during development and differentiation of metazoan organisms. On the other hand, dysregulation of Notch1 signaling is associated with many different types of cancer as well as tumor angiogenesis, making Notch1 a potential therapeutic target. PRINCIPAL FINDINGS: Here we report the in vitro activities of inhibitory Notch1 monoclonal antibodies derived from cell-based and solid-phase screening of a phage display library. Two classes of antibodies were found, one directed against the EGF-repeat region that encompasses the ligand-binding domain (LBD), and the second directed against the activation switch of the receptor, the Notch negative regulatory region (NRR). The antibodies are selective for Notch1, inhibiting Jag2-dependent signaling by Notch1 but not by Notch 2 and 3 in reporter gene assays, with EC(50) values as low as 5+/-3 nM and 0.13+/-0.09 nM for the LBD and NRR antibodies, respectively, and fail to recognize Notch4. While more potent, NRR antibodies are incomplete antagonists of Notch1 signaling. The antagonistic activity of LBD, but not NRR, antibodies is strongly dependent on the activating ligand. Both LBD and NRR antibodies bind to Notch1 on human tumor cell lines and inhibit the expression of sentinel Notch target genes, including HES1, HES5, and DTX1. NRR antibodies also strongly inhibit ligand-independent signaling in heterologous cells transiently expressing Notch1 receptors with diverse NRR "class I" point mutations, the most common type of mutation found in human T-cell acute lymphoblastic leukemia (T-ALL). In contrast, NRR antibodies failed to antagonize Notch1 receptors bearing rare "class II" or "class III" mutations, in which amino acid insertions generate a duplicated or constitutively sensitive metalloprotease cleavage site. Signaling in T-ALL cell lines bearing class I mutations is partially refractory to inhibitory antibodies as compared to cell-penetrating gamma-secretase inhibitors. CONCLUSIONS/SIGNIFICANCE: Antibodies that compete with Notch1 ligand binding or that bind to the negative regulatory region can act as potent inhibitors of Notch1 signaling. These antibodies may have clinical utility for conditions in which inhibition of signaling by wild-type Notch1 is desired, but are likely to be of limited value for treatment of T-ALLs associated with aberrant Notch1 activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rumi Is a CAP10 Domain Glycosyltransferase that Modifies Notch and Is Required for Notch Signaling
Acar, M., Jafar-Nejad, H., Takeuchi, H., Rajan, A., Ibrani, D., Rana, N. A., Pan, H., Haltiwanger, R. S., & Bellen, H. J. (2008) · Cell · doi:10.1016/j.cell.2007.12.016 · Cited by 306
Cited by
Notch signaling: simplicity in design, versatility in function
Andersson, E. R., Sandberg, R., & Lendahl, U. (2011) · Development · doi:10.1242/dev.063610 · Cited by 950
Notch Signaling in Development, Tissue Homeostasis, and Disease
Siebel, C., & Lendahl, U. (2017) · Physiological Reviews · doi:10.1152/physrev.00005.2017 · Cited by 978
The genetics and molecular biology of T-ALL
Girardi, T., Vicente, C., Cools, J., & De Keersmaecker, K. (2017) · Blood · doi:10.1182/blood-2016-10-706465 · Cited by 355
Notch inhibitors for cancer treatment
Espinoza, I., & Miele, L. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.02.003 · Cited by 273
The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia
Sanchez-Martin, M., & Ferrando, A. (2017) · Blood · doi:10.1182/blood-2016-09-692582 · Cited by 256
Metadata
- Authors
- Aste-Amézaga, M., Zhang, N., Lineberger, J. E., Arnold, B. A., Toner, T. J., Gu, M., Huang, L., Vitelli, S., Vo, K. T., Haytko, P., Zhao, J. Z., Baleydier, F., L'Heureux, S., Wang, H., Gordon, W. R., Thoryk, E., Andrawes, M. B., Tiyanont, K., Stegmaier, K., Roti, G., Ross, K. N., Franlin, L. L., Wang, H., Wang, F., Chastain, M., Bett, A. J., Audoly, L. P., Aster, J. C., Blacklow, S. C., & Huber, H. E.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-02-08
- Volume
- 5
- Issue
- 2
- Pages
- e9094
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2015425841
- Cited by
- 178
- References
- 1
- FWCI
- 7.56
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Characterization of Notch1 Antibodies That Inhibit Signaling of Both Normal and Mutated Notch1 Receptors. https://app.cochat.ai/papers/10.1371/journal.pone.0009094
- The paper
- Aste-Amézaga, M., Zhang, N., Lineberger, J. E., Arnold, B. A., Toner, T. J., Gu, M., Huang, L., Vitelli, S., Vo, K. T., Haytko, P., Zhao, J. Z., Baleydier, F., L'Heureux, S., Wang, H., Gordon, W. R., Thoryk, E., Andrawes, M. B., Tiyanont, K., Stegmaier, K., . . . Huber, H. E. (2010). Characterization of Notch1 Antibodies That Inhibit Signaling of Both Normal and Mutated Notch1 Receptors. PLoS ONE. https://doi.org/10.1371/journal.pone.0009094
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.